Want to see JP:4884 full AI Analyst Report?
Top Page
Kringle Pharma, Inc.
(4884)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥449.00
▲(18.47% Upside)
Action:Reiterated
Date:08/21/26
The score is held back primarily by weak financial performance (ongoing losses, declining recent revenue, and sustained cash burn), only partly offset by a low-leverage balance sheet. Technicals provide a meaningful lift due to strong momentum and price strength versus moving averages, but overbought signals temper that benefit. Valuation remains challenged due to negative earnings and no indicated dividend support.
Positive Factors
Low Leverage
The absence of reported debt limits fixed financial obligations and reduces solvency risk, giving Kringle Pharma greater flexibility to fund research, clinical development, and operations despite ongoing losses.
Negative Factors
Persistent Unprofitability
Sustained operating and net losses indicate that the current business model is not self-sustaining. Continued deficits may constrain investment capacity, erode equity, and increase dependence on future financing or successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The absence of reported debt limits fixed financial obligations and reduces solvency risk, giving Kringle Pharma greater flexibility to fund research, clinical development, and operations despite ongoing losses.
Read all positive factors
Kringle Pharma, Inc. (4884) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.82B
Dividend YieldN/A
Average Volume (3M)51.60K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth372.42%
EPS Growth22.75%
CountryJP
Employees17
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-110.74
Shares Outstanding8,593,200
10 Day Avg. Volume53,170
30 Day Avg. Volume51,600
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kringle Pharma, Inc. Business Overview & Revenue Model
Company Description
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious ...
How the Company Makes Money
Publicly available, company-specific details on Kringle Pharma, Inc.’s current revenue model, primary revenue streams, and material partnerships (e.g., disclosed licensing/royalty structures, collaboration payments, or marketed product sales) are ...
Kringle Pharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 341.47M | 72.22M | 80.04M | 69.25M | 391.83M | 289.76M |
| Gross Profit | 234.20M | 72.22M | 0.00 | 0.00 | 303.42M | 218.16M |
| EBITDA | -806.45M | -909.45M | -817.88M | -888.76M | -426.17M | -357.88M |
| Net Income | -808.44M | -916.25M | -756.45M | -854.15M | -331.83M | -301.17M |
Balance Sheet | ||||||
| Total Assets | 2.00B | 2.08B | 2.76B | 2.62B | 3.21B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.70B | 1.62B | 2.31B | 2.14B | 2.76B | 2.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 744.51M | 770.11M | 648.92M | 596.95M | 419.50M | 129.48M |
| Stockholders Equity | 1.25B | 1.31B | 2.11B | 2.02B | 2.79B | 2.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | -661.17M | -689.10M | 15.80M | -560.92M |
| Operating Cash Flow | -755.78M | -755.78M | -661.17M | -689.10M | 15.80M | -560.92M |
| Investing Cash Flow | -154.01M | -154.01M | -121.36M | -120.88M | -254.38M | 0.00 |
| Financing Cash Flow | 84.14M | 84.14M | 838.23M | 69.16M | 603.11M | 595.90M |
Kringle Pharma, Inc. Technical Analysis
Positive
379.00
Price Trends
350.34
Positive
388.75
Positive
393.62
Positive
Market Momentum
29.95
Negative
70.37
Negative
85.61
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4884, the sentiment is Positive. The current price of 379 is below the 20-day moving average (MA) of 391.00, above the 50-day MA of 350.34, and below the 200-day MA of 393.62, indicating a bullish trend. The MACD of 29.95 indicates Negative momentum. The RSI at 70.37 is Negative, neither overbought nor oversold. The STOCH value of 85.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4884.
Kringle Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ¥3.82B | -4.09 | ― | ― | 372.42% | 22.75% | |
49 Neutral | ¥4.98B | -4.07 | ― | ― | 1135.58% | 2.37% | |
48 Neutral | ¥143.78B | -39.65 | -6.88% | ― | 0.62% | 27.66% | |
44 Neutral | ¥9.30B | -7.81 | -32.74% | ― | 74.24% | -7.78% | |
43 Neutral | ¥2.53B | -1.39 | ― | ― | -62.54% | 10.12% | |
40 Underperform | ¥1.49B | -0.78 | ― | ― | ― | 20.94% |
* General Sector Average
JP:4884
Kringle Pharma, Inc.
453.00
-36.00
-7.36%
JP:4587
Peptidream
1,114.50
-386.00
-25.72%
JP:4571
NanoCarrier Co., Ltd.
105.00
-42.00
-28.57%
JP:4591
Ribomic, Inc.
93.00
-14.00
-13.08%
JP:4598
Delta-Fly Pharma, Inc.
105.00
-472.00
-81.80%
JP:4881
FunPep Company Limited
53.00
-62.00
-53.91%
Kringle Pharma, Inc. Corporate Events
Kringle Pharma Boosts Sales but Warns of Deeper Full-Year Losses
Aug 10, 2026
Kringle Pharma reported a sharp rise in net sales to ¥323 million for the nine months ended June 30, 2026, up more than fivefold year on year, but continued to post operating and net losses, with a nine-month loss of ¥631 million and a b...
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
Jul 24, 2026
Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremepermin alfa, a recombinant human hepatocyte growth factor, in patients with acute cervical spinal cord injury. The multicenter, open-label study will enroll 10 adult...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.